The effects of vitamin D and probiotic co-supplementation on mental health parameters and metabolic status in type 2 diabetic patients with coronary heart disease: A randomized, double-blind, placebo-controlled trial.
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Jun 8;84(Pt A):50-55. doi: 10.1016/j.pnpbp.2018.02.007. Epub 2018 Feb 9.
Raygan F1, Ostadmohammadi V2, Bahmani F3, Asemi Z4.
Suspect Probiotic ==> improved gut ==> improved bioavailablity of standard Vitamin D
- Suspect that gut-friendly Vitamin D, which is more available for those with poor guts (about 1/3 of all Vitamin D releasete health problems) would have similar benefits
- Alternately, give more vitamin D (see 50,000 IU weekly below)
- Overview Diabetes and vitamin D
- Diabetes category
- Vitamin D is aided by probiotics (review of RCTs) – Dec 2020
- Hypothesis: vitamin D and probiotics will reduce type II diabetes – Jan 2013 Hypothesis seems correct
- Vitamin D receptor functionality improved with probiotics – Sept 2015 perhaps probiotics increases VDR
- Vitamin D injection is far better than oral for diabetics (poor gut) – RCT March 2017
- Diabetes treated if given enough vitamin D (example: 50,000 IU weekly) – review of RCT - Jan 2017
- Diabetics helped by vitamin D in 5 ways – meta-analysis June 2018
- Diabetes treated and prevented by more than 2,000 IU of vitamin D (need more and gut-friendly) - meta-analyses 2018
- Magnesium is associated with prevention and treatment of Diabetes – Meta-analysis Aug 2016
- Omega-3 might manage T2 Diabetes – March 2018
- Diabetes 50X less likely if 30 ng of Vitamin D and intense exercise – April 2018
- Suspect that Vitamin D + Magnesium + Omega-3 + Intense exercise will nicely prevent/ treat many health problems
- Most Diabetics getting 40,000 IU of vitamin D weekly did not get to 30 ng (needed gut-friendly form) - RCT June 2020
- Diabetes helped somewhat by weekly 50,000 IU of vitamin D (5 ways to improve) – RCT Aug 2021
- Prediabetes reduced by weekly 60,000 IU of Vitamin D – RCT Jan 2021
- Diabetic inflammation reduced by Vitamin D (30,000 IU weekly) – RCT July 2020
- 100,000 IU of Vitamin D3 given monthly for 4 months to diabetics – RCT Dec 2019
- Type 2 Diabetes inflammation reduced by 50,000 IU of Vitamin D bi-weekly and resistance training – RCT – June 2019
- Prediabetes both prevented and treated by monthly Vitamin D, etc.
- Peripheral diabetic neuropathy helped by weekly 50,000 IU vitamin D – Jan 2019
- Diabetic nephropathy (Kidney) treated by 50,000 IU of vitamin D weekly – RCT Jan 2019
- Vitamin D treatment of diabetes (50,000 IU every 2 weeks) augmented by probiotic – RCT June 2018
- Waist size reduced 3 cm by Vitamin D in those with Metabolic Syndrome – Jan 2017
- HbA1c levels (Diabetes) reduced by monthly 50,000 IU of vitamin D – Dec 2017
- Gestational Diabetes treated with 50,000 IU every two weeks – RCT Sept 2016
- Prediabetes reduced by monthly 60,000 IU of vitamin D – RCT May 2015
- Pain of Diabetic Neuropathy reduced with weekly 50,000 IU vitamin D– CT Feb 2015
- Type 1 diabetes helped with 50,000 IU of vitamin D every two weeks – Nov 2014
- Gestational Diabetes reduced with 50,000 IU of vitamin D every 3 weeks and daily Calcium – RCT June 2014
- Blood pressure in diabetics reduced by 12 weekly doses of 50,000 IU vitamin D – RCT Jan 2014
- 50,000 IU Vitamin D weekly Improves Mood, Lowers Blood Pressure in Type 2 Diabetics – Oct 2013
- Insulin resistance during pregnancy improved with 50,000 IU of vitamin D every 2 weeks – RCT April 2013
Diabetes + Heart Failure + Chronic Pain + Depression + Autism + Breast Cancer + Colon Cancer + Prostate Cancer + BPH (prostate) + Preeclampsia + Premature Birth + Falls + Cognitive Decline + Respiratory Tract Infection + Influenza + Tuberculosis + Chronic Obstructive Pulmonary Disease + Lupus + Inflammatory Bowel Syndrome + Urinary Tract Infection + Poor Sleep + Growing Pain + Multiple Sclerosis + PMS + Schizophrenia + Endometriosis + Smoking 27 problems
This study was carried out to evaluate the effects of vitamin D and probiotic co-supplementation on mental health parameters and metabolic status in diabetic people with coronary heart disease (CHD).
This randomized, double-blind, placebo-controlled trial was carried out among 60 diabetic people with CHD, aged 45-85 years old. Subjects were randomly allocated into two groups to receive either 50,000 IU vitamin D every 2 weeks plus 8 × 109 CFU/g probiotic of Lactocare Zisttakhmir Co (n = 30) or placebo (n = 30) for 12 weeks. Fasting blood samples were obtained at baseline and after the 12-week intervention to determine metabolic profiles.
After the 12-week intervention, compared with the placebo, vitamin D and probiotic co-supplementation resulted in significant improvements in
- beck depression inventory total score (-2.8 ± 3.8 vs. -0.9 ± 2.1, P = 0.01),
- beck anxiety inventory scores (-2.1 ± 2.3 vs. -0.8 ± 1.4, P = 0.009) and
- general health questionnaire scores (-3.9 ± 4.1 vs. -1.1 ± 3.4, P = 0.005).
Compared with the placebo, vitamin D and probiotic co-supplementation resulted in significant reductions in
- serum insulin levels (-2.8 ± 3.8 vs. +0.2 ± 4.9 μIU/mL, P = 0.009),
- homeostasis model of assessment-estimated insulin resistance (-1.0 ± 1.6 vs. -0.1 ± 1.5, P = 0.02),
and a significant increase in
- serum 25-OH-vitamin D (+11.8 ± 5.9 vs. +0.1 ± 1.4 ng/mL, P < 0.001),
- the quantitative insulin sensitivity check index (+0.03 ± 0.04 vs. -0.001 ± 0.01, P = 0.003) and
- serum HDL-cholesterol levels (+2.3 ± 3.5 vs. -0.5 ± 3.8 mg/dL, P = 0.004).
In addition, changes in
- serum high sensitivity C-reactive protein (hs-CRP) (-950.0 ± 1811.2 vs. +260.5 ± 2298.2 ng/mL, P = 0.02),
- plasma nitric oxide (NO) (+1.7 ± 4.0 vs. -1.4 ± 6.7 μmol/L, P = 0.03) and
- plasma total antioxidant capacity (TAC) (+12.6 ± 41.6 vs. -116.9 ± 324.2 mmol/L, P = 0.03)
in the supplemented group were significantly different from the changes in these indicators in the placebo group.
Overall, vitamin D and probiotic co-supplementation after 12 weeks among diabetic people with CHD had beneficial effects on mental health parameters, serum hs-CRP, plasma NO, TAC, glycemic control and HDL-cholesterol levels.
CLINICAL TRIAL REGISTRATION NUMBER: http://www.irct.ir: IRCT2017073033941N4.